Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 763-772

  Koda, K ^a   Ago, Y ^a   Yano, K ^a   Nishimura, M ^a   Kobayashi, H ^a   Fukada, A ^a   Takuma, K ^a   Matsuda, T ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

galantamine; mice; muscarinic receptor; N desmethylclozapine; oxotremorine; prefrontal cortex; prepulse inhibition (PPI); social isolation

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; DOPAMINE; GALANTAMINE; MUSCARINIC M1 RECEPTOR; NICOTINIC RECEPTOR; OXOTREMORINE; SCOPOLAMINE; TELENZEPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; ENZYME ACTIVITY; HIPPOCAMPUS; HYPOTHERMIA; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; SOCIAL ISOLATION; STARTLE REFLEX;

ACETYLCHOLINESTERASE; ANIMALS; BODY TEMPERATURE; CHOLINESTERASE INHIBITORS; CLOZAPINE; GABA ANTAGONISTS; GALANTAMINE; MALE; MICE; MICRODIALYSIS; MOTOR ACTIVITY; MUSCARINIC AGONISTS; NICOTINE; NICOTINIC AGONISTS; OXOTREMORINE; PARASYMPATHOLYTICS; PIRENZEPINE; RECEPTORS, MUSCARINIC; SENSORY GATING; SOCIAL ISOLATION; STARTLE REACTION;

EID: 78651433135     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01080.x     Document Type: Article

References (50)

1. Ago Y, Sakaue M, Baba A, Matsuda T, (2002). Selective reduction by isolation rearing of 5-HT 1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J Neurochem 83: 353-359.
2. Ago Y, Sato M, Nakamura S, Baba A, Matsuda T, (2006). Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex. J Pharmacol Sci 102: 419-422.
3. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, et al. (2008). Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression. Neuropharmacology 55: 1355-1363.
4. Ago Y, Arikawa S, Yata M, Yano K, Abe M, Takuma K, et al. (2009). Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity. Synapse 63: 7-14.
5. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
6. Allen TB, McEvoy JP, (2002). Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159: 1244-1245.
7. Ballmaier M, Casamenti F, Zoli M, Pepeu G, Spano P, (2001). Selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis impairs prepulse inhibition of acoustic startle. Neuroscience 108: 299-305.
8. Ballmaier M, Casamenti F, Scali C, Mazzoncini R, Zoli M, Pepeu G, et al. (2002). Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Neuroscience 114: 91-98.
9. Beeri R, Andres C, Lev-Lehman E, Timberg R, Huberman T, Shani M, et al. (1995). Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curr Biol 5: 1063-1071.
10. Bora E, Veznedaroǧlu B, Kayahan B, (2005). The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Pharmacol 28: 139-141.
11. Bosch D, Schmid S, (2008). Cholinergic mechanism underlying prepulse inhibition of the startle response in rats. Neuroscience 155: 326-335.
12. Bymaster FP, Heath I, Hendrix JC, Shannon HE, (1993). Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16-24.
13. 2+ signals and neurotransmitter release. Mol Pharmacol 64: 1217-1226.
14. Dirks A, Groenink L, Schipholt MI, van der Gugten J, Hijzen TH, Geyer MA, et al. (2002). Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry 51: 583-590.
15. Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA, (1987). Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 242: 257-262.
16. Ellman GL, Courtney KD, Andres V, Featherstone RM, (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
17. Eltze M, Gonne S, Riedel R, Schlotke B, Schudt C, Simon WA, (1985). Pharmacological evidence for selective inhibition of gastric acid secretion by telenzepine, a new antimuscarinic drug. Eur J Pharmacol 112: 211-224.
18. Fone KC, Porkess MV, (2008). Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev 32: 1087-1102.
19. Franklin KBJ, Paxinos G, (1997). The Mouse Brain in Stereotaxic Coordinates. Academic Press, Inc.: San Diego, CA.
20. Friedman JI, (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174: 45-53.
21. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, et al. (2003). A double blind placebo controlled trail of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51: 349-357.
22. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J, et al. (1999). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 1692-1697.
23. Jones CK, Shannon HE, (2000a). Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. Eur J Pharmacol 391: 105-112.
24. Jones CK, Shannon HE, (2000b). Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 294: 1017-1023.
25. Kawasaki T, Ishihara K, Ago Y, Nakamura S, Itoh S, Baba A, et al. (2006). Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur J Pharmacol 542: 92-99.
26. Koda K, Ago Y, Kawasaki T, Hashimoto H, Baba A, Matsuda T, (2008). Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 196: 293-301.
27. Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY, (2005). N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M 1 muscarinic receptors. Neuropsychopharmacology 30: 1986-1995.
28. Li Z, Prus AJ, Dai J, Meltzer HY, (2009). Differential effects of M 1 and 5-hydroxytryptamine 1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330: 948-955.
29. Rosse RB, Deutsch SI, (2002). Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25: 272-275.
30. Sakaue M, Ago Y, Baba A, Matsuda T, (2003). The 5-HT 1A receptor agonist, MKC-242, reverse isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 170: 73-79.
31. Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305: 1024-1036.
32. Sánchez C, Lembøl HL, (1994). The involvement of muscarinic receptor subtypes in the mediation of hypothermia, tremor, and salivation in male mice. Pharmacol Toxicol 74: 35-39.
33. Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J, (1998). In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M 1 agonist and M 2 /M 3 antagonist in vitro. Psychopharmacology (Berl) 137: 233-240.
34. Sarter M, Bruno JP, (1997). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 23: 28-46.
35. Sato M, Ago Y, Koda K, Nakamura S, Kawasaki T, Baba A, et al. (2007). Role of postsynaptic serotonin 1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex. Eur J Pharmacol 559: 155-160.
36. Shiba K, Ogawa K, Kinuya S, Yajima K, Mori H, (2006). A simple and rapid radiochemical choline acetyltransferase (ChAT) assay screening test. J Neurosci Methods 157: 98-102.
37. Snape MF, Misra A, Murray TK, De Souza RJ, Williams JL, Cross AJ, et al. (1999). A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology 38: 181-193.
38. Sur C, Mallorga PJ, Wittmann M, Jacobsen MA, Pascarella D, Williams JB, et al. (2003). N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674-13679.
39. Thomsen M, Wörtwein G, Fink-Jensen A, Woldbye DP, Wess J, Caine SB, (2007). Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M 5 muscarinic acetylcholine receptor knockout mice. Psychopharmacology 192: 97-110.
40. Thomsen M, Wess J, Fulton BS, Fink-Jensen A, Caine SB, (2010). Modulation of prepulse inhibition through both M 1 and M 4 muscarinic receptors in mice. Psychopharmacology 208: 401-416.
41. Ukai M, Okuda A, Mamiya T, (2004). Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. Eur J Pharmacol 492: 183-187.
42. Varty GB, Walters N, Cohen-Williams M, Carey GJ, (2001). Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. Eur J Pharmacol 424: 27-36.
43. Varty GB, Powell SB, Lehmann-Masten V, Buell MR, Geyer MA, (2006). Isolation rearing of mice induces deficits in prepulse inhibition of the startle response. Behav Brain Res 169: 162-167.
44. Wang F, Chen H, Sun X, (2009). Age-related spatial cognitive impairment is correlated with a decrease in ChAT in the cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci Lett 454: 212-217.
45. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177: 207-216.
46. Weiss S, Tzavara ET, Davis RJ, Nomikos GG, Michael McIntosh J, Giros B, et al. (2007). Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice. Neuropharmacology 52: 1496-1508.
47. Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA, (2009). Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M 4 receptor knockout mice and attenuated in muscarinic M 1 receptor knockout mice. Eur J Pharmacol 603: 147-149.
48. Wu MF, Jenden DJ, Fairchild MD, Siegel JM, (1993). Cholinergic mechanisms in startle and prepulse inhibition: effects of the false cholinergic precursor N-aminodeanol. Behav Neurosci 107: 303-316.
49. Yano K, Koda K, Ago Y, Kobayashi H, Takuma K, Matsuda T, (2009). Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol 156: 173-180.
50. Zarrindast MR, Barghi-Lashkari S, Shafizadeh M, (2001). The possible cross-tolerance between morphine-and nicotine-induced hypothermia in mice. Pharmacol Biochem Behav 68: 283-289.